Latest revenue
$237.5M
as of 2026-03-31
Latest net income
$29.5M
as of 2026-03-31
Net margin
12.4%
as of 2026-03-31
ActaClear Score
Computed from 5 years of SEC fundamentals + latest market data, ranked within Pharmaceutical Preparations (528 peers). 10 = best in industry, 5 = median, 0 = worst. Refreshed Jun 7, 2026.
Fair value · DCF
DCF: 10-year forecast of free cash flow, discounted at the company's WACC, with a Gordon-growth terminal at year 10. FCF is proxied by last fiscal-year net income (proper FCF needs CFO − CapEx by year, which we don't store yet). Drag the slider to test your own growth thesis — the dominant assumption in any DCF is what comes next, not what the math does with it. Beta defaults to 1.0 when not reported.
Community sentiment
Where do you think ANIP is heading?
Price · 5Y
Live market
delayed ≤15 min- Market cap
- $1.98B
- Enterprise value
- $2.09B
- P/E (trailing)
- 25.3×
- Forward P/E
- —
- P/B
- 3.52×
- Dividend yield
- 0.0%
- 52-wk high
- $99.50
- 52-wk low
- $61.17
- Beta
- —
- Shares out
- 24.4M
5-year trend
What this company does
Item 1. Business ANI Pharmaceuticals is a diversified bio-pharmaceutical company. The Company's mission is “Serving Patients, Improving Lives” by developing, manufacturing, and commercializing therapeutics through its Rare Disease, Generics, and Brands businesses. On September 16, 2024, the Company acquired Alimera Sciences, Inc. ("Alimera"). In connection with the acquisition, the Company added two new products, ILUVIEN® ("ILUVIEN") and YUTIQ® ("YUTIQ"). See Note 3 "Business Combination" in the notes to the consolidated financial statements in Part II, Item 8 of this Annual Report on Form 10-K. During March 2025, the FDA approved an expanded label for ILUVIEN to include an indication for…
AI summary unavailable — showing raw filing excerpt
Generated from ANIP's filing dated 2026-02-27
Key risks
Table of Contents Item 1A. Risk Factors Risk Factor Summary Investing in our common stock involves a high degree of risk. Below is a summary of the principal risks that could adversely affect our business, financial position and operating results: •Our approved products, including Cortrophin Gel and ILUVIEN, may not achieve commercialization at levels of market acceptance that will allow us to maintain profitability; •To the extent our ongoing and continuing efforts to commercialize Cortrophin Gel, ILUVIEN, and our other products for which we have received marketing approval are unsuccessful, our business, financial condition, and results of operations will be negatively impacted; •The…
AI summary unavailable — showing raw filing excerpt
Generated from ANIP's filing dated 2026-02-27
Profitability
Operating margin
12.6%
13130.2%Net margin
8.9%
394.2%Return on equity
14.5%
438.5%Return on assets
5.4%
476.9%Leverage
Debt / equity
1.66×
15.4%Long-term debt / equity
0.54×
24.4%Debt / assets
62.5%
5.8%Earnings tracker
| Quarter | Revenue | YoY | Net income | YoY | Net margin |
|---|---|---|---|---|---|
Q1 2026 2026-03-31 | $237.5M | +20.5% | $29.5M | +88.1% | 12.4% |
Q4 2025 2025-12-31 | $247.1M | +29.6% | $27.5M | +204.9% | 11.1% |
Q3 2025 2025-09-30 | $227.8M | +53.6% | $26.6M | +422.8% | 11.7% |
Q2 2025 2025-06-30 | $211.4M | +53.1% | $8.5M | +473.8% | 4.0% |
Q1 2025 2025-03-31 | $197.1M | +43.4% | $15.7M | -13.9% | 8.0% |
Q4 2024 2024-12-31 | $190.6M | — | $-26.2M | — | -13.7% |
Q3 2024 2024-09-30 | $148.3M | +12.5% | $-8.2M | -183.0% | -5.6% |
Q2 2024 2024-06-30 | $138.0M | +18.4% | $-2.3M | -136.6% | -1.7% |
Year-over-year change vs the same fiscal quarter one year prior. Revenue + net income sourced from SEC 10-Q / 10-K filings — no analyst-consensus dependency.
Industry trend
Pharmaceutical Preparations · SIC 2834
Your notes
Keep private notes on ANIP — thesis, target price, catalysts to watch.
Visible only to you. Never shared. Never used to train AI.
Insider activity
Insider buying
$0
Insider selling
$48.7M
Net activity
−$48.7M
Distinct insiders
15
Open-market trades over the last 365 days.
Recent transactions
Source: SEC Form 4 filings. Officers, directors, and 10%+ owners must disclose share transactions within two business days. RSU grants and tax-withholding rows are excluded by default — compensation activity is not a trading signal.
Who owns ANIP
Institutional value
$814.6M
Total shares held
10.9M
Distinct holders
164
-117 vs prior
As of
2026-03-31
Prior: 2025-12-31
Filers with $100M+ AUM disclose holdings 45 days after quarter end.
Top institutional holders
| # | Manager | Shares | Value | QoQ change | Action |
|---|---|---|---|---|---|
| 1 | BlackRock, Inc. | 2.7M | $211.3M | +85.8K (+3.2%) | Added |
| 2 | VANGUARD CAPITAL MANAGEMENT LLC | 823.1K | $63.3M | — | New |
| 3 | DIMENSIONAL FUND ADVISORS LP | 531.2K | $40.8M | +43.5K (+8.9%) | Added |
| 4 | UBS Group AG | 497.7K | $38.3M | +346.9K (+230.1%) | Added |
| 5 | Nuveen, LLC | 402.4K | $30.9M | +15.3K (+3.9%) | Added |
| 6 | VANGUARD PORTFOLIO MANAGEMENT LLC | 376.0K | $28.9M | — | New |
| 7 | Walleye Capital LLC | 366.1K | $28.2M | +248.8K (+212.1%) | Added |
| 8 | Global Alpha Capital Management Ltd. | 361.2K | $27.8M | -228.9K (-38.8%) | Trimmed |
| 9 | WILLIAM BLAIR INVESTMENT MANAGEMENT, LLC | 327.3K | $25.2M | +10.6K (+3.3%) | Added |
| 10 | Invesco Ltd. | 324.3K | $24.9M | +134.5K (+70.9%) | Added |
| 11 | DEUTSCHE BANK AG\ | 319.7K | $24.6M | -72.9K (-18.6%) | Trimmed |
| 12 | KENNEDY CAPITAL MANAGEMENT LLC | 294.0K | $22.6M | +80.2K (+37.5%) | Added |
| 13 | BANK OF MONTREAL /CAN/ | 230.1K | $17.7M | +10.7K (+4.9%) | Added |
| 14 | TEACHER RETIREMENT SYSTEM OF TEXAS | 220.2K | $16.9M | +68.9K (+45.6%) | Added |
| 15 | JPMORGAN CHASE & CO | 220.2K | $16.2M | -24.5K (-10.0%) | Trimmed |
| 16 | abrdn plc | 206.1K | $15.9M | -34.7K (-14.4%) | Trimmed |
| 17 | Penn Capital Management Company, LLC | 179.7K | $13.8M | +42.3K (+30.8%) | Added |
| 18 | CITIGROUP INC | 144.3K | $11.1M | -27.7K (-16.1%) | Trimmed |
| 19 | Russell Investments Group, Ltd. | 138.9K | $10.7M | +12.5K (+9.8%) | Added |
| 20 | PRINCIPAL FINANCIAL GROUP INC | 129.1K | $9.9M | +20.7K (+19.1%) | Added |
Source: SEC Form 13F-HR. Positions aggregated across sub-managers within each firm. Options (puts/calls) excluded — common stock only.
Top questions investors are asking
Coming once ANIP's latest filing finishes processing.
Sign in to vote. Votes use 7-day half-life decay.
Sign in to tap. 7-day half-life decay.